---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-002881"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:10:15.541310+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte Biotech shareholders elect all five directors and approve auditor ratification at 2024 annual meeting

## Summary
- Quorum of 53.41% of outstanding shares represented at the April 29, 2024 annual meeting.
- All five director nominees elected: Silverman, Schechter, Abecassis, Weinstein, and Walker, each with approximately 88-93% of votes cast For.
- Ratification of Marcum LLP as independent auditor approved with 4,387,273 For, 109,167 Against, 18,447 Abstain.
- Non-binding advisory vote on executive compensation passed with 1,922,352 For, 186,215 Against, 50,866 Abstain.

## SEC filing metadata
- accession: 0001683168-24-002881
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316824002881/0001683168-24-002881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316824002881/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-002881
- JSON: https://secwatch.observer/filing/0001683168-24-002881.json
- Plain text: https://secwatch.observer/filing/0001683168-24-002881.txt

## Key facts
- Shareholder Votes
  PharmaCyte Biotech, Inc. shareholders approved Approval of Executive Compensation at the 2024-04-29 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2024-04-29
  source text: Proposal 3. Approval of Executive Compensation. The approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. For Against Abstain Non-Votes Broker Non-Votes 1,922,352 186,215 50,866 0 2,355,454
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316824002881/0001683168-24-002881-index.htm
- Shareholder Votes
  PharmaCyte Biotech, Inc. shareholders approved Election of Directors at the 2024-04-29 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2024-04-29
  source text: Proposal 1. Election of Directors. The election of five directors, each to hold office until the annual meeting of stockholders for the year ended April 30, 2025 or until their respective successor is elected and qualified. Nominee For Withheld Broker Non-Votes Joshua N. Silverman 1,892,894 266,539 2,355,454 Jonathan L. Schechter 2,064,472 94,961 2,355,454 Michael M. Abecassis 1,579,782 579,651 2,355,454 Robert Weinstein 2,022,363 137,070 2,355,454 Wayne R. Walker 2,060,785 98,648 2,355,454
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316824002881/0001683168-24-002881-index.htm
- Shareholder Votes
  PharmaCyte Biotech, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2024-04-29 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2024-04-29
  source text: Proposal 2. Ratification of Selection of Independent Registered Public Accounting Firm. The ratification of the selection by the audit committee of the board of directors of Marcum LLP as the independent registered public accounting firm of the Company for the fiscal year ending April 30, 2024. For Against Abstain 4,387,273 109,167 18,447
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316824002881/0001683168-24-002881-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.